CN111249228B - 包含释放一氧化氮的前列酰胺的眼用组合物 - Google Patents
包含释放一氧化氮的前列酰胺的眼用组合物 Download PDFInfo
- Publication number
- CN111249228B CN111249228B CN202010145208.8A CN202010145208A CN111249228B CN 111249228 B CN111249228 B CN 111249228B CN 202010145208 A CN202010145208 A CN 202010145208A CN 111249228 B CN111249228 B CN 111249228B
- Authority
- CN
- China
- Prior art keywords
- ophthalmic
- solution
- polyethylene glycol
- ester
- propen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 140
- 229960002470 bimatoprost Drugs 0.000 title description 22
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title description 21
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 87
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 87
- -1 6- (nitrooxy) - Chemical compound 0.000 claims abstract description 74
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 73
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 71
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims abstract description 71
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000002904 solvent Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 52
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 34
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 27
- 239000004327 boric acid Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003937 drug carrier Substances 0.000 claims description 24
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 21
- 239000000600 sorbitol Substances 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000012929 tonicity agent Substances 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 24
- 239000002997 ophthalmic solution Substances 0.000 description 74
- 239000000243 solution Substances 0.000 description 69
- 229940054534 ophthalmic solution Drugs 0.000 description 54
- 238000009472 formulation Methods 0.000 description 47
- 239000008215 water for injection Substances 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 27
- 229920001684 low density polyethylene Polymers 0.000 description 25
- 229940099514 low-density polyethylene Drugs 0.000 description 25
- 239000004702 low-density polyethylene Substances 0.000 description 25
- 230000000845 anti-microbial effect Effects 0.000 description 23
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical class O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 22
- 239000000546 pharmaceutical excipient Substances 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 210000001508 eye Anatomy 0.000 description 20
- 230000004410 intraocular pressure Effects 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 229940072106 hydroxystearate Drugs 0.000 description 19
- 235000010356 sorbitol Nutrition 0.000 description 18
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 17
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- 239000003755 preservative agent Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 14
- 229920000053 polysorbate 80 Polymers 0.000 description 13
- 230000002335 preservative effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 229940009662 edetate Drugs 0.000 description 11
- 239000003889 eye drop Substances 0.000 description 11
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 11
- 229940068968 polysorbate 80 Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 210000001742 aqueous humor Anatomy 0.000 description 10
- 150000003180 prostaglandins Chemical class 0.000 description 10
- 208000010412 Glaucoma Diseases 0.000 description 9
- 206010030043 Ocular hypertension Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000004034 viscosity adjusting agent Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 7
- NTQMJNDRYSYWNJ-BPXWCPHMSA-N [(e,3s)-1-[(1r,2r,3s,5r)-2-[(z)-7-(ethylamino)-7-oxohept-2-enyl]-3,5-dihydroxycyclopentyl]-5-phenylpent-1-en-3-yl] 6-nitrooxyhexanoate Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](OC(=O)CCCCCO[N+]([O-])=O)CCC1=CC=CC=C1 NTQMJNDRYSYWNJ-BPXWCPHMSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229960004716 idoxuridine Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- YFHHIZGZVLHBQZ-KDACTHKWSA-N 17-phenyl-trinor-prostaglandin F2alpha Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)CC1=CC=CC=C1 YFHHIZGZVLHBQZ-KDACTHKWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000008364 bulk solution Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001522 polyglycol ester Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000005588 Kraus reaction Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18290082.9 | 2018-07-12 | ||
| EP18290082 | 2018-07-12 | ||
| CN201910622356.1A CN110237031B (zh) | 2018-07-12 | 2019-07-10 | 包含释放一氧化氮的前列酰胺的眼用组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910622356.1A Division CN110237031B (zh) | 2018-07-12 | 2019-07-10 | 包含释放一氧化氮的前列酰胺的眼用组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111249228A CN111249228A (zh) | 2020-06-09 |
| CN111249228B true CN111249228B (zh) | 2022-05-03 |
Family
ID=63012964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010145208.8A Active CN111249228B (zh) | 2018-07-12 | 2019-07-10 | 包含释放一氧化氮的前列酰胺的眼用组合物 |
| CN201910622356.1A Active CN110237031B (zh) | 2018-07-12 | 2019-07-10 | 包含释放一氧化氮的前列酰胺的眼用组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910622356.1A Active CN110237031B (zh) | 2018-07-12 | 2019-07-10 | 包含释放一氧化氮的前列酰胺的眼用组合物 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US10688073B2 (https=) |
| EP (2) | EP3718535B1 (https=) |
| JP (4) | JP6672512B2 (https=) |
| KR (1) | KR102861273B1 (https=) |
| CN (2) | CN111249228B (https=) |
| AR (1) | AR115734A1 (https=) |
| AU (2) | AU2019300203B2 (https=) |
| BR (1) | BR112021000240A2 (https=) |
| CA (1) | CA3105989A1 (https=) |
| CY (1) | CY1123706T1 (https=) |
| DK (1) | DK3593788T3 (https=) |
| ES (2) | ES2847853T3 (https=) |
| HR (2) | HRP20251098T1 (https=) |
| HU (2) | HUE072927T2 (https=) |
| LT (1) | LT3593788T (https=) |
| MA (2) | MA52258B1 (https=) |
| MD (2) | MD3593788T2 (https=) |
| MX (2) | MX2021000411A (https=) |
| MY (1) | MY205816A (https=) |
| PH (1) | PH12020552112A1 (https=) |
| PL (2) | PL3718535T3 (https=) |
| PT (1) | PT3593788T (https=) |
| RS (2) | RS61348B1 (https=) |
| SG (1) | SG11202100064WA (https=) |
| SI (1) | SI3593788T1 (https=) |
| SM (2) | SMT202100034T1 (https=) |
| TW (1) | TWI839364B (https=) |
| WO (1) | WO2020011845A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019300203B2 (en) * | 2018-07-12 | 2025-01-30 | Nicox S.A. | Ophthalmic compositions containing a nitric oxide releasing prostamide |
| EP4404936A1 (en) * | 2021-09-20 | 2024-07-31 | Nicox SA | Nitric oxide releasing prostamide as neuroprotective agent |
| JP7665073B1 (ja) | 2024-04-05 | 2025-04-18 | ロート製薬株式会社 | 容器に収容してなる眼科用組成物 |
| US20260053768A1 (en) * | 2024-05-07 | 2026-02-26 | Maher Hadaya | Sustained Nitric Oxide Releasing Drug Delivery Systems |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013435A2 (fr) * | 2007-07-20 | 2009-01-29 | Laboratoires Thea | Solution ophtalmique à base de prostaglandines sans conservateur |
| CN101835473A (zh) * | 2007-10-16 | 2010-09-15 | 太阳医药高级研发有限公司 | 新型眼药组合物 |
| CN102099330A (zh) * | 2008-05-09 | 2011-06-15 | 尼科克斯公司 | 供给氧化氮的前列酰胺 |
| CN103764120A (zh) * | 2011-06-29 | 2014-04-30 | 阿勒根公司 | 聚乙二醇15羟基硬脂酸酯制剂 |
| CN105012231A (zh) * | 2014-04-30 | 2015-11-04 | 四川科伦药物研究院有限公司 | 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法 |
| CN105380901A (zh) * | 2015-11-18 | 2016-03-09 | 侯宇华 | 一种他氟前列素滴眼剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011002688A (es) | 2008-09-12 | 2011-04-12 | Critical Pharmaceuticals Ltd | Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel. |
| US20130267591A1 (en) * | 2010-05-07 | 2013-10-10 | Sun Pharma Advanced Research Company Limited | Novel ophthalmic compositions |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| CA2841644A1 (en) | 2011-08-02 | 2013-02-07 | Cipla Limited | Pharmaceutical composition comprising ebastine and fluticasone |
| AU2019300203B2 (en) * | 2018-07-12 | 2025-01-30 | Nicox S.A. | Ophthalmic compositions containing a nitric oxide releasing prostamide |
-
2019
- 2019-07-10 AU AU2019300203A patent/AU2019300203B2/en active Active
- 2019-07-10 MD MDE20200084T patent/MD3593788T2/ro unknown
- 2019-07-10 EP EP20172140.4A patent/EP3718535B1/en active Active
- 2019-07-10 CA CA3105989A patent/CA3105989A1/en active Pending
- 2019-07-10 MA MA52258A patent/MA52258B1/fr unknown
- 2019-07-10 DK DK19185400.9T patent/DK3593788T3/da active
- 2019-07-10 KR KR1020217004141A patent/KR102861273B1/ko active Active
- 2019-07-10 ES ES19185400T patent/ES2847853T3/es active Active
- 2019-07-10 MD MDE20210162T patent/MD3718535T2/ro unknown
- 2019-07-10 MX MX2021000411A patent/MX2021000411A/es unknown
- 2019-07-10 SM SM20210034T patent/SMT202100034T1/it unknown
- 2019-07-10 PL PL20172140.4T patent/PL3718535T3/pl unknown
- 2019-07-10 EP EP19185400.9A patent/EP3593788B1/en active Active
- 2019-07-10 US US16/508,028 patent/US10688073B2/en active Active
- 2019-07-10 CN CN202010145208.8A patent/CN111249228B/zh active Active
- 2019-07-10 PL PL19185400T patent/PL3593788T3/pl unknown
- 2019-07-10 SI SI201930023T patent/SI3593788T1/sl unknown
- 2019-07-10 WO PCT/EP2019/068511 patent/WO2020011845A1/en not_active Ceased
- 2019-07-10 MY MYPI2021000130A patent/MY205816A/en unknown
- 2019-07-10 TW TW108124327A patent/TWI839364B/zh active
- 2019-07-10 CN CN201910622356.1A patent/CN110237031B/zh active Active
- 2019-07-10 HU HUE20172140A patent/HUE072927T2/hu unknown
- 2019-07-10 HU HUE19185400A patent/HUE052747T2/hu unknown
- 2019-07-10 JP JP2019128085A patent/JP6672512B2/ja active Active
- 2019-07-10 PT PT191854009T patent/PT3593788T/pt unknown
- 2019-07-10 HR HRP20251098TT patent/HRP20251098T1/hr unknown
- 2019-07-10 SM SM20250425T patent/SMT202500425T1/it unknown
- 2019-07-10 SG SG11202100064WA patent/SG11202100064WA/en unknown
- 2019-07-10 RS RS20210008A patent/RS61348B1/sr unknown
- 2019-07-10 MA MA48919A patent/MA48919B1/fr unknown
- 2019-07-10 RS RS20250698A patent/RS67054B1/sr unknown
- 2019-07-10 LT LTEP19185400.9T patent/LT3593788T/lt unknown
- 2019-07-10 BR BR112021000240-5A patent/BR112021000240A2/pt unknown
- 2019-07-10 ES ES20172140T patent/ES3036636T3/es active Active
- 2019-07-10 AR ARP190101947A patent/AR115734A1/es unknown
-
2020
- 2020-03-04 JP JP2020036665A patent/JP7080268B2/ja active Active
- 2020-03-11 US US16/815,923 patent/US11020368B2/en active Active
- 2020-12-07 PH PH12020552112A patent/PH12020552112A1/en unknown
-
2021
- 2021-01-05 CY CY20211100004T patent/CY1123706T1/el unknown
- 2021-01-11 MX MX2023007091A patent/MX2023007091A/es unknown
- 2021-01-11 US US17/146,057 patent/US12186295B2/en active Active
- 2021-01-26 HR HRP20210138TT patent/HRP20210138T1/hr unknown
- 2021-03-29 US US17/216,195 patent/US12178793B2/en active Active
-
2022
- 2022-05-24 JP JP2022084562A patent/JP7397910B2/ja active Active
-
2023
- 2023-12-01 JP JP2023203763A patent/JP2024023498A/ja active Pending
-
2024
- 2024-11-15 US US18/949,815 patent/US20250073196A1/en active Pending
-
2025
- 2025-04-29 AU AU2025203019A patent/AU2025203019A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013435A2 (fr) * | 2007-07-20 | 2009-01-29 | Laboratoires Thea | Solution ophtalmique à base de prostaglandines sans conservateur |
| CN101835473A (zh) * | 2007-10-16 | 2010-09-15 | 太阳医药高级研发有限公司 | 新型眼药组合物 |
| CN102099330A (zh) * | 2008-05-09 | 2011-06-15 | 尼科克斯公司 | 供给氧化氮的前列酰胺 |
| CN103764120A (zh) * | 2011-06-29 | 2014-04-30 | 阿勒根公司 | 聚乙二醇15羟基硬脂酸酯制剂 |
| CN105012231A (zh) * | 2014-04-30 | 2015-11-04 | 四川科伦药物研究院有限公司 | 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法 |
| CN105380901A (zh) * | 2015-11-18 | 2016-03-09 | 侯宇华 | 一种他氟前列素滴眼剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma;Francesco Impagnatiello1 et al.;《British Journal of Pharmacology》;20180418;第176卷(第8期);第1079–1089页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7397910B2 (ja) | 一酸化窒素放出プロスタミドを含有する眼科用組成物 | |
| KR101845107B1 (ko) | 스쿠알라민 안약 제제 | |
| RU2781022C2 (ru) | Офтальмологические композиции, содержащие простамид, высвобождающий окись азота | |
| HK40030606A (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40030606B (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40013822B (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40013822A (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40018890B (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40018890A (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| WO2024241345A1 (en) | Ophthalmic suspension composition of brinzolamide and latanoprost | |
| JPWO2001087298A1 (ja) | 水性液剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40030606 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |